MediBeacon's Transdermal GFR System Receives China Approval, Opening Major Market for Point-of-Care Kidney Function Testing
核心洞察
MediBeacon (搜索) received regulatory approval from China's NMPA to sell its Transdermal GFR System, including Lumitrace (搜索) injection, marking a significant milestone for point-of-care kidney function assessment.
The system addresses limitations of current kidney function tests by providing transdermal measurement without being affected by muscle mass, diet, or demographic factors that can lead to misclassification.
China represents a major market opportunity with chronic kidney disease affecting an estimated 11% of the country's 1.4 billion population.
MediBeacon (搜索) Inc. announced on October 21, 2025, that China's National Medical Products Administration (NMPA) has approved its Lumitrace (搜索) (relmapirazin) injection, completing regulatory clearance for the company's Transdermal GFR System in the world's most populous country. The approval opens access to a market where chronic kidney disease affects an estimated 11% of China's 1.4 billion people.
The Transdermal GFR System represents a first-in-kind technology for point-of-care assessment of kidney function in patients with normal or impaired renal function. The system will be available for sale in China before the end of 2025, according to the company.
Revolutionary Approach to Kidney Function Assessment
The MediBeacon (搜索) TGFR system comprises three components: the Lumitrace (搜索) injection, the MediBeacon TGFR Monitor, and the MediBeacon TGFR Sensor. Together, these components assess kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body through transdermal detection.
Lumitrace (搜索) injection is a non-radioactive, non-iodinated pyrazine-based compound engineered to be inert, highly fluorescent, and possess the clearance properties of a GFR tracer agent. The system records Lumitrace fluorescence intensity transdermally through a sensor placed on the skin, taking 2.5 fluorescent readings per second.
"The benefit of Lumitrace (搜索) is that it doesn't interact with medications, is cleared by GFR, and importantly, is agnostic to a patient's demographic information," said Dr. Richard Solomon, the Patrick Professor of Medicine and Director of the Division of Nephrology and Hypertension at University of Vermont Medical Center.
Addressing Clinical Limitations
Current kidney function assessment relies on estimated Glomerular Filtration Rate (eGFR) derived from blood draws or urine samples measuring serum creatinine or Cystatin C levels. These tests can be impacted by muscle mass, diet, hydration status, medication use, and other non-renal inputs that may lead to misclassification of kidney function in patients.
While measured GFR (mGFR) exists, its use remains limited due to requirements for serial blood sampling and sophisticated laboratory analysis, driving associated high costs. The transdermal approach aims to achieve the benefits of mGFR without these challenges.
"Kidney function is often assessed reactively after abnormal labs given the limitations with tools today," Solomon noted. "Transdermal GFR can fundamentally impact kidney disease management through the assessment of a patient's GFR at the point of care without the use of estimating equations and has the potential to transform patient care and outcomes."
Clinical Validation and Market Strategy
In a phase 2 investigational study, mGFR deduced from Lumitrace (搜索) matched that of mGFR deduced from iohexol over a range of GFR values, according to a peer-reviewed article published in the October 2024 issue of Kidney International.
The China approval follows FDA clearance of the MediBeacon (搜索) TGFR system in January 2025. In February, the NMPA had previously approved the MediBeacon TGFR Monitor and MediBeacon TGFR Sensor, with Lumitrace (搜索) injection requiring separate drug approval.
MediBeacon (搜索) established a commercial and clinical development partnership with Huadong Medicine (搜索) in July 2019, positioning the company to introduce the technology into Chinese clinical practice.
"Full China approval is a major step forward in our commitment to expanding access to transdermal GFR globally," said Steven Hanley, CEO and Co-Founder of MediBeacon (搜索). "China represents a significant opportunity, and we look forward to providing access to our technology with the goal of improving patient management."
Intellectual Property and Future Applications
MediBeacon (搜索) owns over 60 granted U.S. patents and over 245 granted patents worldwide providing extensive coverage of the TGFR system, including Lumitrace (搜索) injection, sensor technology, and algorithms. The company's proprietary pyrazine platform and sensor technology have potential applications in gastroenterology, ophthalmology, and surgery that are in various stages of clinical development.